Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells

Biochemical Pharmacology

Volumn 78, Issue 9, 2009, Pages 1115-1126

  Mistafa, Oras ^a   Stenius, Ulla ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Akt; Atorvastatin; Chemotherapy; P2X7; Pancreatic cancer

Indexed keywords

ATORVASTATIN; FLUOROURACIL; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PRAVASTATIN; PROTEIN KINASE B; PURINERGIC P2X7 RECEPTOR; RAF PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; FLUOROURACIL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2X7; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 70249093582     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.016     Document Type: Article

References (40)

1. Chan K.K., Oza A.M., and Siu L.L. The statins as anticancer agents. Clin Cancer Res 9 (2003) 10-19
2. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 5 (2005) 930-942
3. Issat T., Nowis D., Legat M., Makowski M., Klejman M.P., Urbanski J., et al. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int J Oncol 30 (2007) 1413-1425
4. Yao C.J., Lai G.M., Chan C.F., Cheng A.L., Yang Y.Y., and Chuang S.E. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 118 (2006) 773-779
5. Bocci G., Fioravanti A., Orlandi P., Bernardini N., Collecchi P., Del Tacca M., et al. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93 (2005) 319-330
6. Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., Akedo H., et al. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122 (2002) 308-317
7. Gbelcová H., Lenícek M., Zelenka J., Knejzlík Z., Dvoráková G., Zadinová M., et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 122 (2008) 1214-1221
8. Kamiński R., Kozar K., Kopeć M., Basak G., Skierski J.S., Koronkiewicz M., et al. Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 123 (2002) 1747-1748
9. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2006) 1819-1825
10. Khurana V., Sheth A., Caldito G., and Barkin J.S. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 34 (2007) 260-265
11. Holcomb B., Yip-Schneider M.T., Matos J.M., Dixon J., Kennard J., Mahomed J., et al. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J Gastrointest Surg 12 (2008) 288-296
12. Altomare D.A., Tanno S., De Rienzo A., Klein-Szanto A.J., Tanno S., Skele K.L., et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 88 (2003) 470-476
13. Holcomb B., Yip-Schneider M., and Schmidt C.M. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 36 (2008) 225-235
14. Zhao Y., Shen S., Guo J., Chen H., Greenblatt D.Y., Kleeff J., et al. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res 136 (2006) 325-335
15. Pääjärvi G., Roudier E., Crisby M., Högberg J., and Stenius U. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J 19 (2005) 476-478
16. Roudier E., Mistafa O., and Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 5 (2006) 2706-2715
17. Bardeesy N., and DePinho R.A. Pancreatic cancer biology and genetics. Nat Rev Cancer 2 (2002) 897-909
18. Heinemann V. Present and future treatment of pancreatic cancer. Semin Oncol 29 (2002) 23-31
19. Ng S.S.W., Tsao M.S., Chow S., and Hedley D.W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60 (2000) 5451-5455
20. Mistafa O., Högberg J., and Stenius U. Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. BBRC 365 (2008) 131-136
21. Lister M.F., Sharkey J., Sawatzky D.A., Hodgkiss J.P., Davidson D.J., Rossi A.G., et al. The role of the purinergic P2X7 receptor in inflammation. J Inflamm 16 (2007) 4-5
22. Hughes J.P., Hatcher J.P., and Chessell I.P. The role of P2X(7) in pain and inflammation. Purinergic Signal 3 (2007) 163-169
23. Künzli B.M., Berberat P.O., Giese T., Csizmadia E., Kaczmarek E., Baker C., et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Gastrointest Liver Physiol 292 (2007) 223-230
24. Meier R., Alessi D.R., Cron P., Andjelkovic M., and Hemmings B.A. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase. Bh J Biol Chem 272 30 (1997) 491-497
25. Brazil D.P., Park J., and Hemmings B.A. PKB binding proteins. Getting in on the Akt. Cell 111 (2002) 293-303
26. Humphreys B.D., Virginio C., Surprenant A., Rice J., and Dubyak G.R. Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol Pharmacol 54 (1998) 22-32
27. Franke H., Gunther A., Grosche J., Schmidt R., Rossner S., and Reinhardt R. P2X7 receptor expression after ischemia in the cerebral cortex of rats. J Neuropathol Exp Neurol 63 (2004) 686-699
28. Atkinson L., Milligan C.J., Buckley N.J., and Deuchars J. An ATP-gated ion channel at the cell nucleus. Nature 420 (2002) 42
29. Hansen M.R., Krabbe S., and Novak I. Purinergic receptors and calcium signalling in human pancreatic duct cell lines. Cell Physiol Biochem 22 (2008) 157-168
30. Jiang L.H., Mackenzie A.B., North R.A., and Surprenant A. Brilliantblue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 58 (2000) 82-88
31. Mackenzie A.B., Young M.T., Adinolfi E., and Surprenant A. Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors. J Biol Chem 40 (2005) 33968-33976
32. Yang B.C., Wang Y.S., Liu H.S., and Lin S.J. Ras signaling is involved in the expression of Fas-L in glioma. Lab Invest 80 (2000) 529-537
33. Krystal G.W., Sulanke G., and Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1 (2002) 913-922
34. Warshamana-Greene G.S., Litz J., Buchdunger E., Garcia-Echeverria C., Hofmann F., and Krystal G.W. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 11 (2005) 1563-1571
35. Tsurutani J., West K.A., Sayyah J., Gills J.J., and Dennis P.A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65 (2005) 8423-8432
36. Morgan M.A., Parsels L.A., Maybaum J., and Lawrence T.S. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 14 (2008) 6744-6750
37. Ortego M., Bustos C., Hernández-Presa M.A., Tuñón J., Díaz C., Hernández G., et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147 (1999) 253-261
38. Feng Y.-H., Wang L., Wang Q., Li X., Zeng R., and Gorodeski G.I. ATP stimulates GRK-3 phosphorylation and β-arrestin-2-dependent internalization of P2X7 receptor. Am J Physiol Cell Physiol 288 (2005) 1342-1356
39. Denoyelle C., Vasse M., Körner M., Mishal Z., Ganné F., Vannier J.P., et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22 (2001) 1139-1148
40. Dai Y., Khanna P., Chen S., Pei X.Y., Dent P., and Grant S. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 15 (2007) 4415-4423